Omalizumab is approved for:

Moderate to severe persistent asthma in adults and children 6 years and older who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are not adequately controlled with inhaled corticosteroids.
Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults 18 years and older who do not respond adequately to nasal corticosteroids.
IgE-mediated food allergy in adults and children 1 year and older, to reduce allergic reactions (including anaphylaxis) that may occur with accidental exposure to certain foods, used alongside food allergen avoidance.
Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years and older who remain symptomatic despite H1 antihistamine treatment.

For blood cancer patients, omalizumab is not specifically indicated for treatment of blood cancers, but may be considered in those with concurrent severe allergic conditions as described above.

omalizumab

Common brand names

Approved use in